JP2023553935A5 - - Google Patents

Info

Publication number
JP2023553935A5
JP2023553935A5 JP2023535332A JP2023535332A JP2023553935A5 JP 2023553935 A5 JP2023553935 A5 JP 2023553935A5 JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023535332 A JP2023535332 A JP 2023535332A JP 2023553935 A5 JP2023553935 A5 JP 2023553935A5
Authority
JP
Japan
Prior art keywords
seq
mrna
amino acid
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062922 external-priority patent/WO2022125968A1/en
Publication of JP2023553935A publication Critical patent/JP2023553935A/ja
Publication of JP2023553935A5 publication Critical patent/JP2023553935A5/ja
Pending legal-status Critical Current

Links

JP2023535332A 2020-12-11 2021-12-10 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法 Pending JP2023553935A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124060P 2020-12-11 2020-12-11
US63/124,060 2020-12-11
US202063130104P 2020-12-23 2020-12-23
US63/130,104 2020-12-23
US202163165636P 2021-03-24 2021-03-24
US63/165,636 2021-03-24
US202163275424P 2021-11-03 2021-11-03
US63/275,424 2021-11-03
PCT/US2021/062922 WO2022125968A1 (en) 2020-12-11 2021-12-10 Polynucleotides, compositions, and methods for genome editing involving deamination

Publications (2)

Publication Number Publication Date
JP2023553935A JP2023553935A (ja) 2023-12-26
JP2023553935A5 true JP2023553935A5 (cg-RX-API-DMAC10.html) 2025-09-04

Family

ID=80118959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535332A Pending JP2023553935A (ja) 2020-12-11 2021-12-10 脱アミノ化を伴うゲノム編集のためのポリヌクレオチド、組成物、及び方法

Country Status (13)

Country Link
US (1) US20240002820A1 (cg-RX-API-DMAC10.html)
EP (1) EP4259792A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023553935A (cg-RX-API-DMAC10.html)
KR (1) KR20230129996A (cg-RX-API-DMAC10.html)
AU (1) AU2021394998A1 (cg-RX-API-DMAC10.html)
CA (1) CA3205000A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023001684A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009114A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230305A (cg-RX-API-DMAC10.html)
IL (1) IL303506A (cg-RX-API-DMAC10.html)
MX (1) MX2023006876A (cg-RX-API-DMAC10.html)
TW (1) TW202237845A (cg-RX-API-DMAC10.html)
WO (1) WO2022125968A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3220738A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
TW202317764A (zh) * 2021-06-10 2023-05-01 美商英特利亞醫療公司 用於基因編輯之包含內部連接子之經修飾引導rna
EP4426836A1 (en) * 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
EP4426822A2 (en) * 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
EP4638783A2 (en) 2022-12-22 2025-10-29 Intellia Therapeutics, Inc. Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
WO2024227082A1 (en) * 2023-04-26 2024-10-31 Vijay Sankaran Base-editing perturbation screens and uses thereof
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對cd70進行基因修飾之組合物及方法
WO2025081064A2 (en) * 2023-10-11 2025-04-17 Illumina, Inc. Thermophilic deaminase and methods for identifying modified cytosine
KR20260062985A (ko) * 2023-10-13 2026-05-07 스마트셀라 솔루션즈 아베 중간엽 줄기세포를 이용한 비변형 mRNA 작제물의 전달을 위한 방법 및 조성물
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
IL330230A (en) 2023-12-20 2026-08-01 Intellia Therapeutics Inc Engineered T cells
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy
TW202617987A (zh) * 2024-06-26 2026-05-01 美商英特利亞醫療公司 用於基因體編輯之經修飾之嚮導rna
WO2026143185A1 (en) 2024-12-23 2026-07-02 Ensoma Aps Engineered rna-guided dna-binding polypeptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
JP2019515914A (ja) 2016-04-22 2019-06-13 インテリア セラピューティクス,インコーポレイテッド 転写因子4内のトリヌクレオチドリピートと関連する疾患の治療のための組成物および方法
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
JP7383478B2 (ja) 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
WO2019041296A1 (zh) * 2017-09-01 2019-03-07 上海科技大学 一种碱基编辑系统及方法
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
TWI904069B (zh) 2017-09-29 2025-11-11 美商英特利亞醫療公司 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法
JP7832761B2 (ja) 2018-06-08 2026-03-18 インテリア セラピューティクス,インコーポレイテッド 遺伝子編集のための修飾されたガイドrna
MX2021001070A (es) 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
JP7541508B2 (ja) * 2018-08-23 2024-08-28 サンガモ セラピューティクス, インコーポレイテッド 操作された標的特異的な塩基エディター
MX2021003455A (es) 2018-10-02 2021-09-21 Intellia Therapeutics Inc Lípidos con amina ionizables.
CN113166743B (zh) 2018-10-15 2026-04-07 马萨诸塞大学 Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑
CN119285480A (zh) 2018-12-05 2025-01-10 英特利亚治疗股份有限公司 改性的胺脂质
KR20210116526A (ko) * 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
MX2021011690A (es) * 2019-03-28 2022-01-06 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles

Similar Documents

Publication Publication Date Title
AU604634B2 (en) Dog and horse interferons
JP2024525665A5 (cg-RX-API-DMAC10.html)
JP7854334B2 (ja) ファージミドベクター
CA2304254C (en) Trimerising module
CN111757889A (zh) 新型CRISPR/Cas12f酶和系统
JP7663492B2 (ja) 細胞透過性ペプチド
JP2024533311A5 (cg-RX-API-DMAC10.html)
CN114615998B (zh) 缀合物及其用途
AU2013248928A1 (en) Peptides for the binding of nucleotide targets
JP2024542995A5 (cg-RX-API-DMAC10.html)
Freudl et al. Cloning and molecular characterization of the ompA gene from Salmonella typhimurium
JP2023534924A5 (cg-RX-API-DMAC10.html)
JP2024511131A5 (cg-RX-API-DMAC10.html)
JP2022502347A (ja) 細胞透過性ペプチド
US9222107B2 (en) REIC-expressing adenovirus vector
US9809632B2 (en) Universal protein tag for double stranded nucleic acid delivery
CN101524529A (zh) HNF4α诱导分化治疗人体恶性实体瘤
EP3741845B1 (en) Recombinant vaccinia virus and pharmaceutical composition comprising same
WO2025067214A1 (zh) 一种rna甲基化的编辑系统及其应用
EP0596969A1 (en) Igf-ii analogues
CN114438106A (zh) Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用
WO2025045078A1 (zh) 一种用于调控rna甲基化修饰的编辑系统及其应用
US20250332284A1 (en) Modified plant virus system for delivery of nucleic acids into mammalian cells
JP7764502B2 (ja) 環状RNA Circ-ACE2翻訳によるポリペプチド及びその使用
CN103626863B (zh) 一种抑制癌细胞生长的短肽及其编码基因